RS20060473A - Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation - Google Patents

Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation

Info

Publication number
RS20060473A
RS20060473A RSP-2006/0473A RSP20060473A RS20060473A RS 20060473 A RS20060473 A RS 20060473A RS P20060473 A RSP20060473 A RS P20060473A RS 20060473 A RS20060473 A RS 20060473A
Authority
RS
Serbia
Prior art keywords
modulators
inflammation
treatment
furosemide
derivatives
Prior art date
Application number
RSP-2006/0473A
Other languages
English (en)
Inventor
Anne Minnich
Theresa Kuntzweiler
Haifeng Eishingdrelo
Michael Angelastro
Han-Jochen Lang
Original Assignee
Sanofi-Aventis Deutschland Gmbh.,
Aventis Pharmaceuticals Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh.,, Aventis Pharmaceuticals Inc., filed Critical Sanofi-Aventis Deutschland Gmbh.,
Publication of RS20060473A publication Critical patent/RS20060473A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Ćelije domaćini koji eksprimuju HM74 su korišćene za dobijanje furosemid-sličnih moelkula koja imaju agonističku aktivnost i sledeću strukturnu formulu:
RSP-2006/0473A 2004-02-20 2005-02-10 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation RS20060473A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20
PCT/US2005/004108 WO2005082350A1 (en) 2004-02-20 2005-02-10 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation

Publications (1)

Publication Number Publication Date
RS20060473A true RS20060473A (en) 2008-08-07

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2006/0473A RS20060473A (en) 2004-02-20 2005-02-10 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation

Country Status (24)

Country Link
US (2) US7232811B2 (sr)
EP (1) EP1718292A1 (sr)
JP (1) JP2007523166A (sr)
KR (1) KR20060127141A (sr)
CN (1) CN1921845A (sr)
AR (1) AR047747A1 (sr)
AU (1) AU2005216879B2 (sr)
BR (1) BRPI0506792A (sr)
CA (1) CA2557444A1 (sr)
CR (1) CR8528A (sr)
EC (1) ECSP066777A (sr)
IL (1) IL177086A (sr)
MA (1) MA28373A1 (sr)
ME (1) MEP21108A (sr)
MX (1) MXPA06008612A (sr)
NO (1) NO20064237L (sr)
NZ (1) NZ548830A (sr)
RS (1) RS20060473A (sr)
RU (1) RU2006133540A (sr)
SG (1) SG164305A1 (sr)
TN (1) TNSN06234A1 (sr)
TW (1) TW200538109A (sr)
WO (1) WO2005082350A1 (sr)
ZA (1) ZA200606679B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
CA2635261A1 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
KR20080097426A (ko) * 2006-01-18 2008-11-05 쉐링 코포레이션 칸나비노이드 수용체 조절제
WO2008052190A2 (en) * 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
BRPI0506792A (pt) 2007-05-22
WO2005082350A8 (en) 2005-12-08
ECSP066777A (es) 2006-11-16
SG164305A1 (en) 2010-09-29
NO20064237L (no) 2006-09-19
IL177086A (en) 2010-06-16
IL177086A0 (en) 2006-12-10
MXPA06008612A (es) 2007-01-25
US20070213391A1 (en) 2007-09-13
AU2005216879A1 (en) 2005-09-09
ZA200606679B (en) 2008-01-30
US7556931B2 (en) 2009-07-07
CR8528A (es) 2007-06-08
AU2005216879B2 (en) 2009-12-10
NZ548830A (en) 2010-03-26
RU2006133540A (ru) 2008-03-27
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
JP2007523166A (ja) 2007-08-16
US7232811B2 (en) 2007-06-19
TNSN06234A1 (en) 2007-12-03
TW200538109A (en) 2005-12-01
CN1921845A (zh) 2007-02-28
MEP21108A (en) 2010-06-10
CA2557444A1 (en) 2005-09-09
EP1718292A1 (en) 2006-11-08
AR047747A1 (es) 2006-02-15
MA28373A1 (fr) 2006-12-01
WO2005082350A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
SG164305A1 (en) Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
BRPI0511477A (pt) compostos e composições como moduladores de ppar
EA201000046A1 (ru) Замещенные имидазогетероциклы
EA202091999A3 (ru) Применение ингибиторов dpp iv
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
DE602007008237D1 (de) Benzamidderivate und assoziierte verwendungen
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
ATE433966T1 (de) Methylendipiperidinderivate
BRPI0511527A (pt) compostos e composições como moduladores de ppar
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
MX2009003125A (es) Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
ECSP077277A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
CL2008001493A1 (es) Compuesto derivado de 3-(imidazolil)-pirazolo[3,4-b]piridina; procedimiento de prepararcion de dicho compuesto; y su uso para tratar inflamacion, trastornos inmunorregulatorios, entre otros.
UA106600C2 (uk) Карбоксамідні сполуки і способи їхнього застосування
ATE531703T1 (de) Benzochromenderivate
TNSN06235A1 (en) Oxydecahydronaphthalene modulators of hm74
WO2007084542A3 (en) Treatment of inflammatory disorders with triazole compounds
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
WO2007053352A3 (en) Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands